WO1987005506A1 - Immunomodulator for improving commercial performance of domestic animals - Google Patents
Immunomodulator for improving commercial performance of domestic animals Download PDFInfo
- Publication number
- WO1987005506A1 WO1987005506A1 PCT/US1987/000487 US8700487W WO8705506A1 WO 1987005506 A1 WO1987005506 A1 WO 1987005506A1 US 8700487 W US8700487 W US 8700487W WO 8705506 A1 WO8705506 A1 WO 8705506A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- kic
- feed
- animals
- cattle
- protein
- Prior art date
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 79
- 239000002955 immunomodulating agent Substances 0.000 title description 5
- 230000002584 immunomodulator Effects 0.000 title description 5
- 229940121354 immunomodulator Drugs 0.000 title description 5
- 241000283690 Bos taurus Species 0.000 claims abstract description 68
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 40
- 238000004519 manufacturing process Methods 0.000 claims abstract description 31
- BKAJNAXTPSGJCU-UHFFFAOYSA-N 4-methyl-2-oxopentanoic acid Chemical compound CC(C)CC(=O)C(O)=O BKAJNAXTPSGJCU-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229960000890 hydrocortisone Drugs 0.000 claims abstract description 22
- 235000013372 meat Nutrition 0.000 claims abstract description 16
- 230000035584 blastogenesis Effects 0.000 claims abstract description 13
- 235000013601 eggs Nutrition 0.000 claims abstract description 13
- 230000036737 immune function Effects 0.000 claims abstract description 13
- 210000002268 wool Anatomy 0.000 claims abstract description 13
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 12
- 235000013365 dairy product Nutrition 0.000 claims abstract description 12
- 241000283707 Capra Species 0.000 claims abstract description 6
- 241000282898 Sus scrofa Species 0.000 claims abstract description 5
- 244000144977 poultry Species 0.000 claims abstract description 5
- 206010062016 Immunosuppression Diseases 0.000 claims abstract description 3
- 230000001506 immunosuppresive effect Effects 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 72
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 52
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 50
- 108090000623 proteins and genes Proteins 0.000 claims description 41
- 102000004169 proteins and genes Human genes 0.000 claims description 41
- 241000287828 Gallus gallus Species 0.000 claims description 37
- 235000013330 chicken meat Nutrition 0.000 claims description 34
- 239000011734 sodium Substances 0.000 claims description 33
- 229910052708 sodium Inorganic materials 0.000 claims description 32
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 31
- 241001494479 Pecora Species 0.000 claims description 28
- 230000037396 body weight Effects 0.000 claims description 15
- 239000004615 ingredient Substances 0.000 claims description 14
- 244000309466 calf Species 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- 239000011575 calcium Substances 0.000 claims description 6
- 229910052791 calcium Inorganic materials 0.000 claims description 6
- 230000001603 reducing effect Effects 0.000 claims description 6
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 235000016709 nutrition Nutrition 0.000 claims description 4
- 235000013594 poultry meat Nutrition 0.000 claims description 4
- 230000001965 increasing effect Effects 0.000 abstract description 35
- 235000013336 milk Nutrition 0.000 abstract description 18
- 239000008267 milk Substances 0.000 abstract description 18
- 210000004080 milk Anatomy 0.000 abstract description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 10
- 230000008901 benefit Effects 0.000 abstract description 9
- 235000012000 cholesterol Nutrition 0.000 abstract description 9
- 235000015278 beef Nutrition 0.000 abstract description 6
- 235000005911 diet Nutrition 0.000 description 65
- 230000037213 diet Effects 0.000 description 60
- 229960003136 leucine Drugs 0.000 description 42
- 235000018102 proteins Nutrition 0.000 description 32
- 238000002474 experimental method Methods 0.000 description 27
- 239000008188 pellet Substances 0.000 description 25
- 238000011282 treatment Methods 0.000 description 23
- 235000012054 meals Nutrition 0.000 description 20
- 240000008042 Zea mays Species 0.000 description 19
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 19
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 19
- 235000005822 corn Nutrition 0.000 description 19
- 210000004767 rumen Anatomy 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 235000019764 Soybean Meal Nutrition 0.000 description 16
- 150000003839 salts Chemical class 0.000 description 14
- 239000004455 soybean meal Substances 0.000 description 13
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 241000283903 Ovis aries Species 0.000 description 12
- 229920002494 Zein Polymers 0.000 description 12
- 239000005019 zein Substances 0.000 description 12
- 229940093612 zein Drugs 0.000 description 12
- 241000282849 Ruminantia Species 0.000 description 11
- 235000014590 basal diet Nutrition 0.000 description 11
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 8
- 235000019738 Limestone Nutrition 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 239000001506 calcium phosphate Substances 0.000 description 8
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 8
- 229940038472 dicalcium phosphate Drugs 0.000 description 8
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 239000006028 limestone Substances 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 210000000440 neutrophil Anatomy 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 239000011782 vitamin Substances 0.000 description 8
- 229940088594 vitamin Drugs 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 235000019750 Crude protein Nutrition 0.000 description 6
- 208000008939 Pneumonic Pasteurellosis Diseases 0.000 description 6
- 241000282887 Suidae Species 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 229910000019 calcium carbonate Inorganic materials 0.000 description 6
- 159000000007 calcium salts Chemical class 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000007102 metabolic function Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108010068370 Glutens Proteins 0.000 description 5
- 235000013339 cereals Nutrition 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000000378 dietary effect Effects 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 235000021312 gluten Nutrition 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 108010062580 Concanavalin A Proteins 0.000 description 4
- 235000019687 Lamb Nutrition 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000000440 bentonite Substances 0.000 description 4
- 229910000278 bentonite Inorganic materials 0.000 description 4
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 235000020940 control diet Nutrition 0.000 description 4
- 235000021050 feed intake Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 235000013379 molasses Nutrition 0.000 description 4
- 230000000474 nursing effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- 239000011573 trace mineral Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 240000004658 Medicago sativa Species 0.000 description 3
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 108010033737 Pokeweed Mitogens Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 235000013345 egg yolk Nutrition 0.000 description 3
- 210000002969 egg yolk Anatomy 0.000 description 3
- -1 for example Chemical class 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 150000004715 keto acids Chemical class 0.000 description 3
- 125000000468 ketone group Chemical group 0.000 description 3
- 230000006651 lactation Effects 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 208000002289 Bovine Respiratory Disease Complex Diseases 0.000 description 2
- 208000035240 Disease Resistance Diseases 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 235000001188 Peltandra virginica Nutrition 0.000 description 2
- 244000197580 Poria cocos Species 0.000 description 2
- 235000008599 Poria cocos Nutrition 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 235000019742 Vitamins premix Nutrition 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000021243 milk fat Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 238000003359 percent control normalization Methods 0.000 description 2
- 235000021075 protein intake Nutrition 0.000 description 2
- 229940116540 protein supplement Drugs 0.000 description 2
- 235000005974 protein supplement Nutrition 0.000 description 2
- 239000004460 silage Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- 241000517645 Abra Species 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 108010073032 Grain Proteins Proteins 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 239000004236 Ponceau SX Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000003165 abomasum Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000006053 animal diet Substances 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940036811 bone meal Drugs 0.000 description 1
- 239000002374 bone meal Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000029182 enterotoxemia Diseases 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 244000309465 heifer Species 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000020997 lean meat Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 150000002742 methionines Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013384 milk substitute Nutrition 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 125000002640 tocopherol group Chemical group 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229940108519 trasylol Drugs 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
Definitions
- the field of this invention is methods for improving the commercial performance of domestic animals.
- the invention is particularly concerned with the administration of alphaketoisocaproate (KIC) to domestic animals for improving the immune and/or metabolic functions of the animals.
- KIC alphaketoisocaproate
- Keto analogs of essential amino acids have been proposed for use in human nutrition as partial or complete substitutes for the corresponding amino acids, including, for example, leucine, isoleucine, methionine, phenylalanine, and valine.
- leucine leucine
- isoleucine methionine
- phenylalanine and valine.
- the use of such keto analogs was proposed by Dr. MacKenzie Walser as supplementation to protein-reduced diets in uremia. See, for example, Walser, et al., J. Clin. Inv. (1973) 52:678-690.
- Further experiments by Walser and associates demonstrated a nitrogen sparing effect from mixtures of branched-chain keto acids. Saiper and Walser, Metabolism (1977) 26:301-308.
- Patents have issued to Walser on the use of keto analogs of essential amino acids for promotion of protein synthesis and suppression of urea formation in humans.
- U.S. patents 4,100,161 and 4,101,293 A recent review summarized existing knowledge with respect to the administration of branched-chain keto acids to humans. "New Aspects of Clinical Nutrition", pp. 319-324 (Karger, Basel, 1983).
- KIC alpha-ketoisocaproate
- KIC has not been heretofore known as an immunomodulator in humans or animals, nor has it been suggested that KIC can be used to reduce plasma cortisol (hydrocortisone), or that it can be used to favorably alter immune function by enhancing blastogenesis of T lymphocytes.
- T lymphocytes have important functions in immunological defense against microorganisms. See, for example, Williams et al., "Hematology", Chap. 102, pages 927-928 (2nd Ed., 1977, McGraw-Hill). In their immune function, T lymphocytes, which are normally quiescent, undergo mitosis with accelerated DNA production. Williams, et al., above cited, pages 882-884. This process of T lymphocyte activation is known as blastogenesis. The degree of blastogenesis activation of T lymphocytes can be determined in vitro using mitogens. The most commonly employed mitogens for this purpose are phytohemagglutin (PHA), pokeweed mitogen (PWM), and concanavalin A (conA). Williams et al., citedabove, pages 895, and 923.
- PHA phytohemagglutin
- PWM pokeweed mitogen
- conA concanavalin A
- the present invention provides a novel method and novel feed compositions for improving the commercial performance of domestic animals.
- the method utilizes alpha-ketoisocaproate (KIC) as an immunomodulator for improving immune function, and/or as a nutrient additive for improving metabolic function.
- KIC alpha-ketoisocaproate
- the administration of KIC favorably alters immune function, as evidenced by enhanced blastogenesis of the T lymphocytes.
- a further effect on immune function is the marked reduction of plasma cortisol.
- the enhancement of lymphocyte blastogenesis is of value in increasing disease resistance. Reduced plasma cortisol is expected to be ameliorating in counteracting stress associated immunodepression in domestic animals, and should be useful for controlling cattle shipping fever.
- KIC-containing feeds In the case of animals being raised for meat production, such as young cattle and sheep, young chickens, and veal calves, KIC can be used as a "growth promotant immunomodulator"--an unprecedented kind of feed additive.
- Improved metabolic function can also be obtained with mature animals, including dairy cattle, wool-producing sheep, and laying chickens.
- the production of milk, wool, and eggs can be improved, while at the same time increasing the disease resistance of the animals.
- nursing domestic mammals such as cattle, sheep, and hogs
- the improvement in the quality and quantity of the milk benefits the offspring.
- a further benefit is that the nursing mother mammals are more disease resistant.
- KIC KIC to cattle prior to shipment
- the administration of KIC to cattle prior to shipment is expected to mitigate the stress-related effects of shipping fever.
- the KIC should be in a nutritionally-utilizable form.
- the KIC should be absorbable in the digestive system, while for parenteral administration a water-soluble form is preferred.
- it may be used in its free acid form, but its sodium, potassium, ammonium, or calcium salts are preferred.
- Ammonium and alkali metal salts are more water-soluble, while alkaline earth metal salts such as calcium salt are less water-soluble.
- KIC Alpha-ketoisocaproate
- Sodium and calcium salts of KIC as supplied commercially are substantially pure compounds and are in the form of dry powders. However, high purity is not necessarily required for the purposes of the present invention.
- KIC powders can be mixed with dry feeds, or for non-ruminant mammals and poultry water-soluble KIC salts can be administered by dissolving in drinking water.
- parenteral administration such as intramuscular injection
- sodium KIC can be dissolved in a sterile water.
- feed use to assure administration at a desired level, it is preferred to mix the dry KIC salt with the dry feed ingredients at a predetermined concentration.
- the KIC salt can be incorporated by dry blending using standard mixing equipment.
- the KIC should be substantially uniformly distributed throughout the feed. After mixing, if desired, the feed material may be further processed, such as by conversion to pellets.
- feed compositions are composed of mixtures of feed ingredients.
- Such mixed feed compositions may comprise complete feeds or feed concentrates. It has been found preferable in promoting metabolic function with KIC to use only limited quantities of proteinaceous feed ingredients which are high in leucine content.
- feed ingredients include blood meals, which may contain 16 to 20% leucine, and corn gluten meal containing 18 to 20% leucine (based on the protein dry weight).
- soybean meal contains only about 8 to 9% leucine, and can therefore be used as a carrier for KIC in the form of a protein supplement.
- the amount of leucine in the diet is not over 12% of the dry weight of the total protein being consumed by the animal.
- the amount of protein can be calculated by determining nitrogen and multi plying by a standard conversion factor of 6.25 (viz. N x (6.25).
- the amount of leucine is limited to less than 10% by weight of total protein. Consequently, in the formulation of complete feeds or feed concentrates which are to provide a major portion of the animal's diet, it is preferred to maintain the leucine content of the feed composition to not over 12% and preferably less than 10% (based on total protein).
- the immune function improvement of KIC can still be obtained at higher leucine levels.
- the method of this invention can comprise orally administering from as low as 0.5 to 2 milligrams (mg) up to as much as 500 to 1000 mg of alpha-ketoisocaproate (KIC) per kilogram of body weight per 24 hours (hrs).
- KIC alpha-ketoisocaproate
- the amount of KIC administered to the animals can range from 1 to 100 mg (Na KIC basis ) per kg body weight per 24 hrs.
- the amounts of KIC should be understood to relate to the sodium salt of KIC as the weight basis, or to a molar equivalent amount of the calcium salt or other salts or derivatives, which are nutritionably absorbable and utilizable.
- the amount of KIC may be specified in relation to the feed composition.
- the admixed feed composition may contain from as low as 0.01 to 0.1 up to 1.5 to 2.0 wt % KIC (Na KIC dry feed weight basis).
- Such feed compositions will usually contain at least 10% protein and may contain up to 24% protein N x 6.25).
- KIC tablets may be coated with animal blood or with corn protein (zein).
- zein corn protein
- Other proteins can be employed as coating materials which are resistant to rumen breakdown.
- Polymer coating may also be used such as those known to protect protein against rumen destruction. (See the rumen-protective coatings described in the U.S. Patents 4,181,708, 4,181,709, and 4,181,710).
- the coating employed should be one which is resistant to the mildly acid environment of the rumen while dissolving in the more acid environment of the abomasum.
- the amount of KIC required can be monitored by increasing the dosage until an appreciable reduction in plasma cortisol is observed.
- a useful range is from 1 to 100 mg KIC per kg body weight per 24 hrs (Na KIC basis).
- the amount administered can be from 2 to 50 mg KIC per kg body weight per 24 hours (NaKIC basis).
- Feed compositions containing such rumen-protected KIC and comprising substantially the entire diet of the ruminants may contain 0.1 to 0.5% KIC (NaKIC and feed dry weight basis). If unprotected KIC is used these amounts should be increased by a factor of 9 to 10.
- KlC-feeding is especially useful in the feeding of female and castrated and intact male cattle and sheep, but it can also be used with male ruminants if raised for meat production.
- Other uses include breeding stock and replacements.
- the method is preferably used with steers and heifers for beef production, and with wethers, rams, and ewes for lamb meat production and/or wool production.
- improvements in meat production in relation to protein intake and/or increased wool production can be obtained.
- With mature sheep which are primarily being raised for wool production the benefit of increased wool production in relation to protein intake is especially valuable.
- an additional advantage can be reducing the cholesterol content of lean meat, and also probably improving carcass quality or grade.
- improvement in T lymphocyte function is obtainable.
- This invention is also usable with calves being raised for veal production.
- veal calves are not ruminants. They are suckling calves which remain monogastric, i.e., they do not develop a rumen, being fed milk or a milk substitute which provides a balanced diet for the veal calves. KIC fed to veal calves is therefore not subject to rumen loss.
- a liquid milk replacer for veal calves may contain from 0.01 to 0.5% (NAKIC basis) KIC based on the dry matter content of the milk replacer, and preferably from 0.01 to 0.5% KIC on the same basis.
- Sodium KIC is preferred because of its water solubility. The limitations on leucine in the diets for the veal calves are preferably observed, as previously described. Lactating Domestic Mammals
- the method and feed compositions of this invention are applicable to dairy cattle being managed for commercial milk production, and the method and feed compositions can also be advantageously used with lactating goats fed for commercial milk production.
- the invention provides a means for improving the milk produced by nursing mammals, including cattle, sheep, goats, horses, and swine. The young mammals being nursed thereby obtain the benefits of greater milk production and increased butterfat content. All of the foregoing instructions about the form and amount of KIC are applicable.
- the feeds employed can be adapted for the particular animal and the purpose for which it is being raised.
- the KIC feeding method of this invention is particulaly suitable for use in raising "broilers", which are hen chickens usually marketed around 10 weeks of age. It is also applicable to the raising of capons.
- the feeding method of this invention may reduce the cholesterol content of the meat in the finished chickens. This cholesterol reducing effect becomes more pronounced as the protein content of the diet is increased, being especially marked with diets containing more protein than normally required for the growth stage of the chickens.
- the chicken feed compositions will usually be composed of mixtures of feed ingredients, including protein-providing ingredients.
- the feed compositions may comprise complete feeds or feed concentrates.
- the feeds preferably should contain at least a normally adequate amount of protein for the age ot the chickens. Diets essentially deficient in protein should be avoided.
- Starter feeds containing at least 22% protein by weight (feed dry basis) are preferred for 0 to 4 weeks of age. Finishing rations used from 5 weeks on may contain a lesser amount of protein, but preferably contain at least 18% protein.
- the amount of leucine in the diet of the chickens is preferred to not over 12% by weight based on the dry weight of the total protein being consumed, and preferably less than 10% by weight.
- the method of this invention as applied to young chickens comprises orally administering at least 0.01 and preferably at least 0.05 weight percent (wt %) of alphaketoisocaproate (KIC), based on the dry weight of the total diet.
- KIC alphaketoisocaproate
- the amount of KIC is referenced to sodium KIC and its molar equivalents.
- the amount of KIC administered to the chickens is from 0.05 to 0.1 up to 0.5 wt % KIC (sodium KIC basis) based on the dry weight of the feed consumed by the chickens. Higher levels of KIC, such as in the range from 0.5 to 1%, could be used but have not been found to provide any added benefit.
- the amount of KIC may be specified in relation to the feed composition.
- admixed feed compositions may contain from 0.05 to 1.0 wt % KIC (sodium KIC basis) in relation to the dry weight of the feed composition.
- the feed compositions preferably contain from 0.1 to 0.5 wt % KIC (sodium KIC basis) of the feed dry weight.
- the feed compositions also preferably contain at least an adequate amount of protein.
- Illustrative feed compositions for use in practicing the present invention witn young chickens are set out below.
- the compositions are specially designed for use with chickens being raised for broiler production.
- Ration A is designed for use from 0 to 4 weeks of age, and Ration B from 4 to 6 or 4 to 8 weeks of age.
- NaKIC or CaKIC is added to these rations in amounts on a dry matter basis equal to 0.1 to 0.2 wt. %.
- the method of this invention can have beneficial effects on both the quantity and quality of the eggs laid.
- the number of eggs laid can be increased.
- the cholesterol content of the egg yolks can be reduced. Both of these advantages can be important in connection with commercial egg production.
- KIC powders can be mixed with dry feeds for dry feed compositions or the water-soluble KIC salts can be administered by dissolving in drinking water.
- Sodium KIC is preferred, and it is preferred to mix the dry KIC salt with the dry chicken feed ingredients at predetermined concentrations.
- the KIC salt can be incorporated by using standard mixing and blending equipment. KIC is probably substantially uniformly distributed throughout the feed. After mixing, if desired, the feed material may be further processed, such as by conversion to pellets.
- complete feed compositions or diets for the laying chickens preferably contain not over 12% leucine based on the total protein being consumed, and less than 10% by weight leucine is believed to be optimum.
- the amount of KIC to be administered to the laying chickens is in general from 0.01 to 1.0 weight percent (wt %) of KIC based on the dry weight of the total feed diet. This amount of KIC is referenced to sodium KIC and its molar equivalents.
- the amount of KIC administered to the laying chickens is from 0.05 to 0.5 wt % KIC (sodium KIC basis) on the dry weight of the feed consumed by the chickens, such as 0.1 to 0.2% NaKIC.
- the amount of KIC may be specified in relation to the feed composition.
- admixed feed compositions may contain from 0.01 to 1.0 wt % KIC (sodium KIC basis) in relation to the dry weight of the feed composition.
- the feed compositions preferably contain from 0.05 to 0.5 wt %.
- KIC sodium KIC
- Such feed compositions will usually contain at least 10% protein and may contain up to 18% protein (N x 6.25).
- Cattle which may be beef cattle or dairy cattle, can be fed KIC as an additive to their feed for several days prior to shipment, such as preferably at least 5 to 10 days, if the cattle have not been regularly receiving KIC-containing feeds.
- the amount of KIC administered can be increased over that used for regular feeding.
- rumen-protected KIC sodium KIC basis
- rumen-protection of the KIC is desirable, as previously described. If sodium KIC is used in unprotected form, the amount orally administered may be increased up to 20 to 500 mg KIC (NaKIC basis) per kilogram of body weight per 24 hours.
- the KIC may be parenterally administered, such as by intramuscular injection. Unprotected KIC can be used. It will probably be preferable to administer two or more injections on successive days prior to shipment.
- the injections may be prepared in a sterile aqueous solution of sodium KIC, and may contain from 50 to 4000 milligrams of sodium KIC per dose.
- KIC KIC
- administration of KIC may be continued by oral feeding. It is believed that this will also be of value in reducing the adverse effects of shipping stress.
- the amount of rumen-protected KIC to be used in the feeds for post-shipment administration can range from .50 to 50 milligrams KIC (sodium KIC basis) per kilogram of body weight.
- the method, feed composition, and results obtainable by the present invention are further illustrated by the following experimental examples.
- the lambs used in Trial 1 consisted of medium-frame crossbred wethers and ewes weighing 26 to 31 kg.
- the lambs used in Trial 2 consisted of medium-framced crossbred rams weighing 18 to 25 kg. Each animal was raised as a single. The lambs were housed in a temperature controlled room in individual pens with nipple waterers. When received, the lambs were vaccinated for enterotoxemia. They were allowed to adjust to the pens and the environment for 10 days. One day before the trial began, the lambs were sheared and placed on their respective dietary treatments. The lambs were allotted blocking by weight and sex into two dietary treatment groups. Growth and feed consumption were measured bi-weekly.
- the SMB (soybean meal-containing) and the CGM (corngluten-containing) diets were fed twice per day in quantities ensuring that feed was before the lambs at all times.
- the diets were calculated to be equivalent to each other with respect to metabolizable protein, ether extract, fiber, and minerals with the exception of calcium and phosphorus.
- the CGM diet contained less calcium (0.68 v. 0.74%) and phosphorus (0.30 v. 0.47%), and had a higher calcium to phosphorus ratio (2.29 v. 1.57) than the SMB diet.
- the CGM diet was calculated to contain slightly more energy (TDN 81.7 vs. 79.0, NEm 1.88 v. 1.86, Neg.
- the CGM diet contained slightly more crude protein on a dry matter basis than did the SBM diet (20.5 v. 19.8%).
- the soybean meal ingredient contained about 3.5 wt % leucine, while the corn gluten meal ingredient contained about 15 wt % leucine.
- the CGM diet was therefore higher in leucine than the SBM diet, containing an estimated 16 wt % leucine as compared with an estimated 8 wt % leucine based on total crude protein in the diet.
- Cows were fed ad libitum a total mixed ration twice daily (7:30 a.m. and 5:30 p.m.) with feed refusals collected before the morning feeding.
- the diet consisted of 31% chopped alfalfa hay, 18% corn silage, and 41% grain mix (as a % of the dry matter).
- the grain mix was calculated to contain 1.55 Meal NE/kg dry matter and 16% crude protein.
- a major portion of the grain protein was from expeller processed soybean meal with higher than usual bypass characteristics.
- the cows were consuming protein in excess of their normal requirements.
- the grain ration contained an estimated 10% leucine (total protein basis), and the complete diet contained an estimated 9% leucine (total protein basis).
- KIC was fed in a mixture which consisted of Na-KIC, corn gluten meal, hvdrogenated soy oil and paraffin in a ratio of 2:1.0:0.1:0.1. The mixture was extruded and formed into crumbles. At least part of the KIC may have escaped rumen degradation with this treatment. Additionally, 100 units of tocopherol were added per gram of Na-KIC to prevent oxidation of KIC. Control animals were fed an equivalent amount of the same mixture but without KIC added.
- control period designated weeks -2 and -1
- all cows received the same diet.
- the trial period extended over the next three weeks (weeks 1, 2, 3) during which cows received either the KIC or control mix top-dressed on their diets twice per day (half the dose in the morning, half in the evening).
- daily milk yield, milk composition, and feed consumption was measured for each cow.
- urinary catheters were inserted and total urine and fecal collections were made for 48 hrs. Results of production and nitrogen balance studies were analyzed statistically using each cow as her own control. The trial effect was measured by subtracting the average control period value from the value during the treatment period. ANOVA was used to detect differences between the KIC-fed and control groups.
- Laying hens (69 weeks of age) were randomly assigned to either a control diet or a diet containing 0.2 wt % KIC (Na). For the next 28 days feed consumption was recorded and eggs collected. Eggs were weighed and analyzed for egg yolk cholesterol. The feed composition is shown in Table C and the results in Table D. The total protein was about 18% on a dry matter basis, and the amount of leucine was about 9% of the protein. The control diet was the same except for the omission of the KIC.
- Soyabean meal (48% protein) 214.0
- Meat & bone meal (50% protein) 20.0
- experiment 3 72 castrated male cattle were allotted to 12 pens of 6 animals each. Three pens were assigned to each treatment: 0.0% KIC, 0.02% KIC, 0.07% KIC, and 0.20% KIC. Animals were fed ad libitum the respective diets for 6 weeks. At the end of the 6-week periods, 100-ml blood samples were collected from each animal, and lymphocyte and neutrophil function were evaluated.
- Sheep in experiments 1 and 2 were fed diets based on a mixture of 48% corn, 5% molasses, 20% alfalfa meal, 0.8% limestone, 0.6% salt-mineral-vitamin mix and ⁇ 25% of a protein supplement (either soybean meal, corn gluten meal, or corn gluten feed).
- the diets were isonitrogenous and analyzed to be -20% crude protein and 89% dry matter.
- the KIC diet consisted of the basal diet to which was added 1% calcium-KIC, whereas the control diet was the basal diet plus 0.25% calcium carbonate.
- the basal cattle diet (experiment 3) consisted of 49% corn, 24% corn-cobs, 18% soybean meal, 7% molasses, 1.3% limestone, 0.25% dicalcium phosphate, 0.23% salt, 0.02% tracemineral premix, and 0.11% vitamin premix.
- the basal diet was supplemented with w/w 0.05% control pellets, 0.04% KIC pellets or 0.4% KIC pellets. All animals consumed ⁇ 10 kg of feed per day, resulting in ⁇ 0, 2, 7, or 20 g of Ca-KIC consumed per animal per day or 0, .02, .07, and .2% KIC of the total diet.
- KIC pellets were made by mixing zein, ethanol, KIC, limestone, bentonite, and water in a ratio of 8.3:7.4:5.2:3: 2.1. This mixture was extruded through a die of 15 mm directly into a vat of liquid nitrogen. The shattered pellets were spread out and allowed to air-dry for 2 days. The pellets were coated with zein (2% w/w) bv spraying with a 30% zein solution made in 80% ethanol. The pellets again were air-dryed. Control pellets were made similarly to the KIC pellets except that the mixture was zein, limestone, ethanol, bentonite, and water in a ratio of 12:12:7.5:2.7:1. When KIC pellets were placed in the rumen (nylon bag technique), 33% of the KIC added was present in the bags after 24 hr of rumen fermentation. It was estimated that uncoated KIC was 95% degraded in the rumen.
- lymphocyte blastogenesis Blood was collected by jugular venapuncture into acid-citrate-dextrose anticoagulant. Lymphocytes and neutrophils were isolated, and lymphocyte blastogenesis and neutrophil function evaluated. KIC was obtained from SOBAC, Paris, France. Zein was purchased from Freeman Industries, Tuckahoe, NY. Each experiment was statistically analyzed by analysis of variance. In sheep experiments, individual animals were the experimental units, whereas pen means were analyzed in the cattle experiment. The changes in lymphocyte blastogenesis are summarized in Table F. In all three experiments, average background blastogenesis was increased in KIC-treated groups.
- KIC phytohemagglutinin
- ConA Concanavalin A
- PWM pokeweek mitogen
- KIC did not alter neutrophil random migration, Staphylococcus aureus ingestion, cytochrome C reduction, iodination, or antibody-dependent cell-mediated cytotoxicity in any experiment, indicating that KIC does not alter neutrophil function. Feed intake in control and KIC-treated animals was not different in any experiment.
- experiment 1 sixteen female pigs weighing 20-30 kg were used. Seven days before study, catheters were surgically placed in the right atria for blood sampling. Animals were housed in individual cages during the recovery period and had free access to water. Preceding the experiment, animals were fed twice daily a basal diet (2% of body weight per feeding). The basal diet consisted of a corn-soybean mix, adequate in all minerals and vitamins and containing approximately 14% crude protein. Test meals were formulated by additions to a basal diet.
- Cortisol was measured by coated tube kits (Gammacoat, Travenol-Genetech Diagnostics, Cambridge, MA). Leucine and KIC were measured by high pressure liquid chromatography. Crystalline leucine was obtained from Sigma Chemical (St. Louis, MO) and KlC-sodium was obtained from . OBAC (Paris, France). Statistical analysis of the individual pig responses was conducted on mean plasma concentrations before the meal (-20 to 0 min) and after the meal (120 to 240 min). When the overall treatment F-value was significant, differences between individual treatments were determined using the pooled SEM and a T-test.
- Table G presents the changes in plasma leucine, KIC and cortisol concentration in pigs before and after ingestion of control, leucine and KIC meals.
- Ingestion of the control meal resulted in a small significant increase in leucine concentration while plasma KIC concentration remained constant.
- Ingestion of the leucine meal caused plasma leucine concentration to increase 4 fold whereas KIC ingestion caused a doubling of leucine concentration.
- Plasma KIC concentration increased from a basal concentration of ⁇ 40 ⁇ M to 90 ⁇ M and over 100 ⁇ M in pigs fed KIC- and leucine-supplemented meals, respectively.
- Plasma cortisol concentration did not change after the control meal (Table G).
- the addition of leucine to the diet resulted in a small decrease in plasma cortisol (-14%, nonsignificant).
- Addition of KIC to the diet, however, resulted in a 40% decrease in cortisol concentration by 240-300 minutes after the meal (p ⁇ .01).
- the treatments consisted of four levels of Ca-KIC in a pelleted supplement: 0%, 0.02%, 0.07%, and 0.20% of the basal diet (0.05% control pellets, 0.04% KIC pellets, 0.14% KIC pellets, and 0.40% KIC pellets).
- the pellets were preweighted and top-dressed on the basal diet twice daily.
- the cattle on the 0.20% KIC were removed from the experiment.
- the cattle were not implanted with a growth promotant nor were ionophores included in the diet.
- the cattle were placed in the feedlot and fed a growing ration for 5 weeks prior to the start of the experiment.
- the cattle were weighed on 2 consecutive days at the beginning and end of the experiment, and every 14 days during the trial.
- the cattle were sold through a commercial beef processing plant when they were appraised by visual examination to grade Choice. Loin eye area and fat thickness over the loin were measured on each carcass. Quality and yield grades, and percent kidney, heart, and lepvic (KHP) fat were estimated by the federal graders.
- KIC pellets resistant to rumen degradation, were made by mixing zein, ethanol, KIC, limestone, bentonite and water in a ratio of 8.3:7.4:5.2: 3:2:1. This mixture was extruded through a die of 15 mm directly into a vat of liquid nitrogen. The shattered pellets were spread out and allowed to air-dry for two days. The dried pellets were coated with zein (2% w/w) by spraying with a 30% zein solution made in 80% ethanol. The pellets again were air-dried.
- Control pellets were made similar to the KIC pellets except that the mixture was zein, limestone, ethanol, bentonite and water in a ratio of 12:12:7.5:2.7:1.
- KIC pellets were placed in the rumen (nylon bag technique), 45% of the KIC added was present in the bags after 36 hr of rumen digestion.
- KIC was obtained from SOBAC, Paris, France. Zein was purchased from Freeman Industries, Tuckahoe, N.Y. Each experiment was statistically analyzed by analysis of variance with three pens per treatment.
- KIC may have significant potential as a feed additive for growing feedlot cattle.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Birds (AREA)
- Fodder In General (AREA)
- Feed For Specific Animals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US838,356 | 1986-03-11 | ||
US838,357 | 1986-03-11 | ||
US06/838,356 US4758593A (en) | 1986-03-11 | 1986-03-11 | Method of feeding ketoisocaproate to lactating domestic mammals |
US06/838,355 US4764531A (en) | 1986-03-11 | 1986-03-11 | Method of feeding ketoisocaproate to laying chickens |
US06/838,357 US4760090A (en) | 1986-03-11 | 1986-03-11 | Method of feeding ketoisocaproate to cattle and sheep |
US838,355 | 1986-03-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1987005506A1 true WO1987005506A1 (en) | 1987-09-24 |
Family
ID=27420276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1987/000487 WO1987005506A1 (en) | 1986-03-11 | 1987-03-09 | Immunomodulator for improving commercial performance of domestic animals |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0258422A1 (en) |
JP (1) | JPS63502835A (en) |
AU (1) | AU7162987A (en) |
WO (1) | WO1987005506A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2623824A (en) * | 1951-07-05 | 1952-12-30 | Ayerst Mckenna & Harrison | Growth promoting agent |
US2879162A (en) * | 1956-10-04 | 1959-03-24 | Du Pont | Augmenting poultry feed |
-
1987
- 1987-03-09 EP EP87901996A patent/EP0258422A1/en not_active Ceased
- 1987-03-09 AU AU71629/87A patent/AU7162987A/en not_active Abandoned
- 1987-03-09 JP JP62501930A patent/JPS63502835A/en active Pending
- 1987-03-09 WO PCT/US1987/000487 patent/WO1987005506A1/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2623824A (en) * | 1951-07-05 | 1952-12-30 | Ayerst Mckenna & Harrison | Growth promoting agent |
US2879162A (en) * | 1956-10-04 | 1959-03-24 | Du Pont | Augmenting poultry feed |
Non-Patent Citations (3)
Title |
---|
K. CHOW, "J. Nutr.", Volume 104 published 1974, see pages 1208-1214. * |
R.K. CHAWLA, "J. Nutr.", Volume 105, published 1975, see pages 798-803. * |
See also references of EP0258422A4 * |
Also Published As
Publication number | Publication date |
---|---|
AU7162987A (en) | 1987-10-09 |
EP0258422A1 (en) | 1988-03-09 |
JPS63502835A (en) | 1988-10-20 |
EP0258422A4 (en) | 1988-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5028440A (en) | Method of raising meat producing animals to increase lean tissue development | |
US5087472A (en) | Feed compositions for domestics animals containing hydroxymethylbutyrate | |
EP2314172A1 (en) | Livestock feed additive and livestock feed composition | |
US4711897A (en) | Animal feed methods and compositions using cysteamine | |
US4835185A (en) | Immunomodulator for improving commercial performance of domestic animals | |
US4760090A (en) | Method of feeding ketoisocaproate to cattle and sheep | |
JP2542655B2 (en) | Mixed feed for animals | |
EP0104630B1 (en) | Animal growth promotant and method of use for animal growth | |
US4534969A (en) | Method for improving lactation in ruminant animals | |
EP0237956B1 (en) | Method of feeding ketoisocaproate to lactating domestic mammals | |
US4454137A (en) | Feed compositions containing copper salts of 2-hydroxypyridine-N-oxides | |
EP4378320A1 (en) | Use of furan formic acid compound in preparing animal feed additive | |
US4414206A (en) | Animal feeds | |
US4258031A (en) | Feed composition containing ronnel and antibiotic A3823 complex and use thereof | |
WO1987005506A1 (en) | Immunomodulator for improving commercial performance of domestic animals | |
EP0596026A1 (en) | Antibiotic feed compositions and method of enhancing feed efficiency and promoting growth in monogastic animals | |
WO2020243975A1 (en) | Use of nutraceutical composition in animal feed | |
Scott | Vitamin K in animal nutrition | |
US4462995A (en) | Pyridyl phosphorothioate compositions and their use as anabolic agents | |
SU1391570A1 (en) | Method of feeding stallion-sires | |
JPS63238020A (en) | Bacillus polymyxa containing drug for livestock administration | |
EP0080854A1 (en) | Method of improving growth of poultry | |
CA1296636C (en) | 2-pyridinol compounds useful as anabolic agents | |
US3719758A (en) | Method of promoting growth and improving feed efficiency in poultry and swine via oral administration of cephalosporin c | |
WO1995022259A1 (en) | Improving growth and lactation of ruminants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1987901996 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1987901996 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1987901996 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1987901996 Country of ref document: EP |